Hysterectomy and Definitive Care for Uterine Fibroids
At a Glance
Hysterectomy is the only definitive treatment for uterine fibroids because removing the uterus prevents fibroids and related symptoms from returning. Choosing it requires weighing surgical risks, the rare possibility of hidden uterine cancer, recovery, and permanent loss of fertility.
For many people with uterine fibroids, the journey through various medications and procedures eventually leads to a decision about hysterectomy. While uterus-sparing options are often the first choice, a hysterectomy remains the only definitive (curative) treatment for fibroids [1]. Because the uterus is removed, the symptoms—and the fibroids—cannot return.
When Hysterectomy is Indicated
A hysterectomy is usually considered the standard of care when other treatments have not provided enough relief or when a patient prioritizes a permanent solution [2]. Common reasons for choosing this path include:
- Persistent Symptoms: Severe bleeding, iron-deficiency anemia, or “bulk” symptoms (like intense pelvic pressure) that continue despite medical or less-invasive therapy [1][3].
- No Desire for Future Pregnancy: For those who have completed their families or do not wish to give birth, hysterectomy provides a high level of satisfaction by permanently ending menstrual cycles and fibroid growth [4][2].
- Failed Uterus-Sparing Procedures: In long-term studies, about 35% of patients who initially chose Uterine Artery Embolization (UAE) eventually required a secondary hysterectomy within 10 years due to persistent or returning symptoms [4].
The Risk of Occult Uterine Sarcoma
One of the most complex parts of a hysterectomy or myomectomy is the possibility of an occult uterine sarcoma. This is a rare, aggressive cancer that can look exactly like a benign fibroid on an ultrasound or MRI [2][5].
- Understanding the Risk: The risk is not the same for everyone; it increases significantly with age and in peri- or postmenopausal patients [6][7]. An ordinary benign fibroid does not generally “turn into” a sarcoma; rather, an occult sarcoma is a separate, rare diagnosis [8]. Crucially, no preoperative imaging or routine biopsy reliably excludes a sarcoma.
Understanding Power Morcellation
When a surgeon performs a minimally invasive hysterectomy (laparoscopic or robotic), they often need to remove a large uterus through very small incisions. To do this, they sometimes use a power morcellator, which is a surgical tool used to divide the tissue into smaller fragments [9].
The FDA Warning
In 2014, the FDA issued a major safety communication regarding these tools. If a patient has an undetected sarcoma and a power morcellator is used, the tool can spread cancerous tissue throughout the abdomen. This can cause the cancer to spread (disseminate) and significantly worsen the patient’s prognosis [10][8].
Because of this, current FDA guidelines state:
- The FDA warns against power morcellation in patients who are postmenopausal or older than 50, or in those who are candidates for en-bloc (intact) tissue removal [9].
- If morcellation is used in appropriately selected patients, it should be done inside a contained tissue-bag system. While this reduces the risk of tissue spread, it does not completely eliminate the possibility of dissemination [9][10].
Types of Hysterectomy and Surgical Decisions
If you and your doctor decide on a hysterectomy, the approach should be the least invasive one possible for your specific anatomy [2].
- Vaginal Hysterectomy: The uterus is removed through the vagina. This is the least invasive option with the fastest recovery, but it is not always possible if the fibroids are very large [11].
- Laparoscopic/Robotic Hysterectomy: Small incisions are made in the abdomen. These offer faster recovery and less pain than open surgery [11][2].
- Abdominal (Open) Hysterectomy: A larger incision is made. This is used for very large uteri or when cancer is suspected and the tissue must be removed entirely intact (en-bloc) to avoid spreading any potential cancer cells [11][9].
Patients should also discuss retaining versus removing the ovaries and cervix. Retaining functioning ovaries usually avoids immediate surgical menopause, while removing them causes it and has long-term implications. Removing the cervix (total hysterectomy) versus retaining it affects postoperative spotting and future cervical-screening needs [11].
Choosing a definitive treatment is a significant step. While it eliminates the burden of fibroids, it also involves a major surgical recovery and the end of fertility. Discussing the trade-offs is essential for a plan that aligns with your health and life goals.
Common questions in this guide
Does a hysterectomy permanently cure uterine fibroids?
When should I consider hysterectomy for fibroids?
Can doctors rule out hidden uterine cancer before fibroid surgery?
What is power morcellation, and why does it matter during hysterectomy?
How is the type of hysterectomy chosen for fibroids?
Should my ovaries and cervix be removed during hysterectomy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Am I a candidate for a minimally invasive hysterectomy, or do the size and number of my fibroids require an abdominal incision?
- 2.Given my age and health history, what is your assessment of my risk for an occult uterine sarcoma?
- 3.If you are planning to use a morcellator, will you be using a contained tissue-bag system?
- 4.If I have my uterus removed, what are the pros and cons of keeping or removing my ovaries and cervix?
- 5.How will we manage my anemia before surgery to ensure I am as healthy as possible for recovery?
- 6.What is the typical recovery timeline for the specific type of hysterectomy you are recommending?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Guideline No. 461: The Management of Uterine Fibroids.
Chen I, Kives S, Randle E, et al.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2025; (47(8)):102970 doi:10.1016/j.jogc.2025.102970.
PMID: 40562356 - 2
The management of uterine leiomyomas.
Vilos GA, Allaire C, Laberge PY, et al.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 2015; (37(2)):157-178 doi:10.1016/S1701-2163(15)30338-8.
PMID: 25767949 - 3
Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228.
Obstetrics and gynecology 2021; (137(6)):e100-e115 doi:10.1097/AOG.0000000000004401.
PMID: 34011888 - 4
Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial.
de Bruijn AM, Ankum WM, Reekers JA, et al.
American journal of obstetrics and gynecology 2016; (215(6)):745.e1-745.e12 doi:10.1016/j.ajog.2016.06.051.
PMID: 27393268 - 5
Prevalence, characteristics, and risk factors of occult uterine cancer in presumed benign hysterectomy.
Desai VB, Wright JD, Gross CP, et al.
American journal of obstetrics and gynecology 2019; (221(1)):39.e1-39.e14 doi:10.1016/j.ajog.2019.02.051.
PMID: 30853364 - 6
Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.
Multinu F, Casarin J, Tortorella L, et al.
American journal of obstetrics and gynecology 2019; (220(2)):179.e1-179.e10 doi:10.1016/j.ajog.2018.11.1086.
PMID: 30447212 - 7
Risk of Undetected Cancer at the Time of Laparoscopic Supracervical Hysterectomy and Laparoscopic Myomectomy: Implications for the Use of Power Morcellation.
Perkins RB, Handal-Orefice R, Hanchate AD, et al.
Women's health issues : official publication of the Jacobs Institute of Women's Health 2016; (26(1)):21-6.
PMID: 26701205 - 8
Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T, Tucker LY, Zaritsky E, et al.
Obstetrics and gynecology 2016; (127(1)):29-39 doi:10.1097/AOG.0000000000001187.
PMID: 26646120 - 9
Morcellation of occulted sarcomas during laparoscopic myomectomy and hysterectomy for patients with large fibroid uterus.
Tinelli A, Farghaly SA
Minerva ginecologica 2018; (70(1)):84-88 doi:10.23736/S0026-4784.17.04149-1.
PMID: 28975775 - 10
Laparoscopic Power Morcellation: Techniques to Avoid Tumoral Spread.
Zapardiel I, Boria F, Halaska MJ, De Santiago J
Journal of minimally invasive gynecology 2021; (28(8)):1442-1443 doi:10.1016/j.jmig.2020.09.012.
PMID: 32961359 - 11
Surgical management of uterine fibroids.
Lewis JM, Wu H, Rojas AC, et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2026; (174(2)):554-578 doi:10.1002/ijgo.71123.
PMID: 42311201
This page is for informational purposes only and does not constitute medical advice about hysterectomy or uterine fibroids. Discuss your individual surgical options, sarcoma risk, fertility goals, and recovery with your gynecologist.
Get notified when new evidence is published on uterine corpus leiomyoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.